An in vitro Evaluation of Cytochrome P450 Inhibition and P-Glycoprotein Interaction with Goldenseal, Ginkgo biloba, Grape Seed, Milk Thistle, and Ginseng Extracts and Their Constituents

Abstract

Drug-herb interactions can result from the modulation of the activities of cytochrome P450 (P450) and/or drug transporters. The effect of extracts and individual constituents of goldenseal, Ginkgo biloba (and its hydrolyzate), grape seed, milk thistle, and ginseng on the activities of cytochrome P450 enzymes CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 in human liver microsomes were determined using enzyme-selective probe substrates, and their effect on human P-glycoprotein (Pgp) was determined using a baculovirus expression system by measuring the verapamil-stimulated, vanadate-sensitive ATPase activity. Extracts were analyzed by HPLC to standardize their concentration(s) of constituents associated with the pharmacological activity, and to allow comparison of their effects on P450 and Pgp with literature values. Many of the extracts/constituents exerted ≥ 50 % inhibition of P450 activity. These include those from goldenseal (normalized to alkaloid content) inhibiting CYP2C8, CYP2D6, and CYP3A4 at 20 μM, ginkgo inhibiting CYP2C8 at 10 μM, grape seed inhibiting CYP2C9 and CYP3A4 at 10 μM, milk thistle inhibiting CYP2C8 at 10 μM, and ginsenosides F₁ and Rh₁ (but not ginseng extract) inhibiting CYP3A4 at 10 μM. Goldenseal extracts/constituents (20 μM, particularly hydrastine) and ginsenoside Rh₁ stimulated ATPase at about half of the activity of the model substrate, verapamil (20 μM). The data suggest that the clearance of a variety of drugs may be diminished by concomitant use of these herbs via inhibition of P450 enzymes, but less so by Pgp-mediated effects.

Abbreviations

HLM: human liver microsomes

Pgp: P-glycoprotein

P_i: inorganic phosphate

Cytochrome P450 - P-glycoprotein - goldenseal - ginkgo - grape seed - milk thistle - ginseng - Hydrastis canadensis - Ginkgo biloba - Vitis vinifera - Silybum marianum - Panax ginseng

References

• 1 Eisenberg D M, Davis R B, Ettner S L, Appel S, Wilkey S, Van Rompay M. et al . Trends in alternative medicine use in the United States, 1990 - 1997.  JAMA. 1998;  280 1569-75.
• 2 Lown K S, Bailey D G, Fontana R J, Janardan S K, Adair C H, Fortlage L A. et al . Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP 3A protein expression.  J Clin Invest. 1997;  99 2545-53.
• 3 Mouly S J, Paine M F, Watkins P B. Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.  J Pharmacol Exp Ther. 2004;  308 941-8.
• 4 Obach R S. Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression.  J Pharmacol Exp Ther. 2000;  294 88-95.
• 5 Dresser G K, Schwarz U I, Wilkinson G R, Kim R B. Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects.  Clin Pharmacol Ther. 2003;  73 41-50.
• 6 Mathews J M, Etheridge A S, Black S R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones.  Drug Metab Dispos. 2002;  30 1153-7.
• 7 Mathews J M, Etheridge A S, Valentine J L, Black S R, Coleman D P, Patel P. et al . Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro .  Drug Metab Dispos. 2005;  33 1555-63.
• 8 Jellin J M, Gregory P, Batz F, Hitchens K. Pharmacist’s Letter/Prescriber’s Letter. Stockton, CA; Natural Medicines Comprehensive Database 2000.
• 9 Hertog M G, Kromhout D, Aravanis C, Blackburn H, Buzina R, Fidanza F. et al . Flavonoid intake and long-term risk of coronary heart disease and cancer in the seven countries study.  Arch Intern Med. 1995;  155 381-6.
• 10 Keli S O, Hertog M G, Feskens E J, Kromhout D. Dietary flavonoids, antioxidant vitamins, and incidence of stroke: the Zutphen study.  Arch Intern Med. 1996;  156 637-42.
• 11 Blumenthal M, Busse W R, Goldberg A, Gruenwald J, Hall T, Riggins C W. et al .The complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines. Austin, TX; American Botanical Council 1998: 563-5.
• 12 Santos-Buelga C, Scalbert A. Proanthcyanidins and tannin-like compounds in human nutrition.  J Food Sci Agric. 2000;  80 1094-117.
• 13 Chatterjee P, Franklin M R. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components.  Drug Metab Dispos. 2003;  31 1391-7.
• 14 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Khan I A. et al . In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes.  Clin Pharmacol Ther. 2005;  77 415-26.
• 15 Lewis D F, Eddershaw P J, Goldfarb P S, Tarbit M H. Molecular modelling of cytochrome P4502D6 (CYP2D6) based on an alignment with CYP102: structural studies on specific CYP2D6 substrate metabolism.  Xenobiotica. 1997;  27 319-39.
• 16 Hollman P C. Bioavailability of flavonoids.  Eur J Clin Nutr. 1997;  51 Suppl 1 S66-9.
• 17 Bokkenheuser V D, Shackleton C H, Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal bacteroides from humans.  Biochem J. 1987;  248 953-6.
• 18 Day A J, DuPont M S, Ridley S, Rhodes M, Rhodes M J, Morgan M R. et al . Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver beta-glucosidase activity.  FEBS Lett. 1998;  436 71-5.
• 19 Walgren R A, Lin J T, Kinne R K, Walle T. Cellular uptake of dietary flavonoid quercetin 4’-beta-glucoside by sodium-dependent glucose transporter SGLT1.  J Pharmacol Exp Ther. 2000;  294 837-43.
• 20 Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract.  Biochem Biophys Res Commun. 2004;  318 1072-8.
• 21 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Cui Y. et al . Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans.  Clin Pharmacol Ther. 2002;  72 276-87.
• 22 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Cui Y. et al . Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba .  Drugs Aging. 2005;  22 525-39.
• 23 Uchida S, Yamada H, Li X D, Maruyama S, Ohmori Y, Oki T. et al . Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers.  J Clin Pharmacol. 2006;  46 1290-8.
• 24 Sridar C, Goosen T C, Kent U M, Williams J A, Hollenberg P F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases.  Drug Metab Dispos. 2004;  32 587-94.
• 25 Gurley B J, Gardner S F, Hubbard M A, Williams D K, Gentry W B, Carrier J. et al . In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.  Clin Pharmacol Ther. 2004;  76 428-40.
• 26 Gurley B, Hubbard M A, Williams D K, Thaden J, Tong Y, Gentry W B. et al . Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.  J Clin Pharmacol. 2006;  46 201-13.
• 27 Tawab M A, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides in humans after oral administration.  Drug Metab Dispos. 2003;  31 1065-71.
• 28 Liu Y, Zhang J W, Li W, Ma H, Sun J, Deng M C. et al . Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes.  Toxicol Sci. 2006;  91 356-64.
• 29 Liu Y, Ma H, Zhang J W, Deng M C, Yang L. Influence of ginsenoside Rh1 and F1 on human cytochrome P450 enzymes.  Planta Med. 2006;  72 126-31.
• 30 Yuan C S, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S. et al . Brief communication: American ginseng reduces warfarin’s effect in healthy patients: a randomized, controlled trial.  Ann Intern Med. 2004;  141 23-7.
• 31 Rautio J, Humphreys J E, Webster L O, Balakrishnan A, Keogh J P, Kunta J R. et al . In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates.  Drug Metab Dispos. 2006;  7 7.
• 32 Maeng H J, Yoo H J, Kim I W, Song I S, Chung S J, Shim C K. P-glycoprotein-mediated transport of berberine across Caco-2 cell monolayers.  J Pharm Sci. 2002;  91 2614-21.
• 33 Gurley B J, Swain A, Barone G W, Williams D K, Breen P, Yates C R. et al . Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans.  Drug Metab Dispos. 2007;  35 240-5.
• 34 Yang C Y, Chao P D, Hou Y C, Tsai S Y, Wen K C, Hsiu S L. Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats.  Food Chem Toxicol. 2006;  44 1572-8.
• 35 Zhang S, Morris M E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport.  J Pharmacol Exp Ther. 2003;  304 1258-67.
• 36 Gurley B J, Barone G W, Williams D K, Carrier J, Breen P, Yates C R. et al . Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans.  Drug Metab Dispos. 2006;  34 69-74.
• 37 Choi C H, Kang G, Min Y D. Reversal of P-glycoprotein-mediated multidrug resistance by protopanaxatriol ginsenosides from Korean red ginseng.  Planta Med. 2003;  69 235-40.
• 38 Benet L Z, Kroetz D L, Sheiner L B. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, editor Goodman & Gilman’s The Pharmacological Basis of Therapeutics. New York, NY; McGraw-Hill 1996: 3-27.